echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb's blockbuster immunotherapy combination receives FDA priority review

    Bristol-Myers Squibb's blockbuster immunotherapy combination receives FDA priority review

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bristol-Myers Squibb (BMS) announced today that the U.


    Lung cancer is the leading cause of cancer death worldwide


    Opdivo is a PD-1 immune checkpoint inhibitor designed to help restore anti-tumor immune responses


    The application is based on the results of the pivotal Phase 3 clinical trial CheckMate-816, in which Opdivo in combination with chemotherapy, when administered preoperatively, demonstrated a pathological complete response (meaning that in surgically resected tissue or There was a statistically significant and clinically meaningful improvement in tissue biopsy samples without any sign of cancer, pCR) and event-free survival (EFS)


    References:

    [1] US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.